Dr. Michael I. Ghilezan

  • MD, PhD
  • Radiation Oncologist
  • Spoken languages English, French, Italian, Romanian

Overview

Michael I. Ghilezan, MD, PhD has a special interest in brachytherapy and has been on the faculty at the Prostate Brachytherapy School of the American Brachytherapy Society (ABS) as well as the educational courses of the American Society for Therapeutic Radiology and Oncology (ASTRO). He has been invited to give more than 90 lectures around the world and has authored and co-authored more than 130 publications and 9 book chapters. Dr. Ghilezan was Principal Investigator on numerous research studies including NIH and RTOG trials. He was a recipient of the Nucletron Award for the best oral presentation at the World Congress of Brachytherapy meeting. Dr. Ghilezan is fluent in English, French, Italian and Romanian.

Career Positions

Current position(s)

  • GenesisCare - Radiation Oncologist, Pontiac, MI

Past position(s)

  • Oakland University William Beaumont School of Medicine, Rose Cancer Institute - Associate Professor, Royal Oak, MI
  • Oakland University William Beaumont School of Medicine, Director of Brachytherapy Services, Royal Oak, MI
  • William Beaumont Hospital - Radiation Oncologist, Royal Oak, MI

Education

Universities

  • University of Medicine and Pharmacy Luliu Hatieganu, PhD Clinical Research and Radiation Physics Program, Cluj-Napoca, Romania/European Institute of Oncology, Milan, Italy
  • University of Medicine and Pharmacy Luliu Hatieganu, Doctor of Medicine, Cluj-Napoca, Romania

Residencies

  • University of Paris Rene Descartes, Radiation Oncology, Paris, France

Expertise And Interests

Interests

  • Prostate, Breast, Lung, Colorectal, Head and Neck Malignancies

Accomplishments

Awards and honors

  • 2004 Nucletron Award at World Congress of Brachytherapy Meeting

Publications

  • Adaptive Dose Recalculation for Prostate Cancer in the Era of Online IGRT IMRT: How Close Is the Planned Radiation Dose to the Delivered Dose?

Clinical studies

Primary Objective To assess the benefit of docetaxel as measured by improvement in freedom from progression (phase II) and subsequently metastasis free survival (phase III) when given in combination with radiation and androgen deprivation in treatment of high risk prostate cancer post-radical prostatectomy.

View Study

Michael Ghilezan's Reviews

Overall

based on 112 Ratings 26 Comments

2020

waiting time for the response from Michael Ghilezan was longer than I expected!

2020

Very happy with them.

2020

Very caring staff and Doctor.

2020

Due to power outage this was a virtual visit. In person would have been better, but then we would have been wearing masks, so it was good not having to wear them and see peoples reactions and expressions.

Read More

Ratings and Comments Powered by NRC Health